These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16830315)

  • 21. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trial of subtherapeutic pergolide in de novo Parkinson's disease.
    Grosset K; Grosset D; Lees A;
    Mov Disord; 2005 Mar; 20(3):363-6. PubMed ID: 15580607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study.
    Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Bellomo G; Belloni G; Grisorio B; Annese M; Bacca D; Francavilla R; Barbarini G
    Hepatology; 1998 Aug; 28(2):374-8. PubMed ID: 9695999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
    Stacy M; Silver D; Mendis T; Sutton J; Mori A; Chaikin P; Sussman NM
    Neurology; 2008 Jun; 70(23):2233-40. PubMed ID: 18519872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
    Tompson D; Oliver-Willwong R
    Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of midazolam and flumazenil on psychomotor function.
    Gupta A; Lind S; Eklund A; Lennmarken C
    J Clin Anesth; 1997 Feb; 9(1):21-5. PubMed ID: 9051541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial.
    Pomier-Layrargues G; Giguère JF; Lavoie J; Perney P; Gagnon S; D'Amour M; Wells J; Butterworth RF
    Hepatology; 1994 Jan; 19(1):32-7. PubMed ID: 8276366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diazepam-induced disruption of classically-conditioned fear-potentiation of late-latency auditory evoked potentials is prevented by flumazenil given before, but not after, CS/US pairing.
    Scaife JC; Hou RH; Samuels ER; Baqui F; Langley RW; Bradshaw CM; Szabadi E
    J Psychopharmacol; 2007 Jan; 21(1):93-101. PubMed ID: 16533870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antagonizing the effect of midazolam by flumazenil in gastroscopy: results of a randomized double blind study].
    Lanius V; Rohde H; Mühlhofer H; Fischer M
    Z Gastroenterol; 1990 Jun; 28(6):267-70. PubMed ID: 2238753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.
    Rabey JM; Prokhorov T; Miniovitz A; Dobronevsky E; Klein C
    Mov Disord; 2007 Feb; 22(3):313-8. PubMed ID: 17034006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease.
    Singer C; Lamb J; Ellis A; Layton G;
    Mov Disord; 2007 Mar; 22(4):476-82. PubMed ID: 17318839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
    Talati R; Reinhart K; Baker W; White CM; Coleman CI
    Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects.
    Ebert U; Oertel R; Kirch W
    Clin Pharmacol Ther; 2000 May; 67(5):538-48. PubMed ID: 10824633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationships between the unified Parkinson's disease rating scale and lower extremity functional performance in persons with early-stage Parkinson's disease.
    Song J; Fisher BE; Petzinger G; Wu A; Gordon J; Salem GJ
    Neurorehabil Neural Repair; 2009 Sep; 23(7):657-61. PubMed ID: 19336530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bilateral impairments of skilled reach-to-eat in early Parkinson's disease patients presenting with unilateral or asymmetrical symptoms.
    Doan JB; Melvin KG; Whishaw IQ; Suchowersky O
    Behav Brain Res; 2008 Dec; 194(2):207-13. PubMed ID: 18692094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease.
    Thomsen TR; Galpern WR; Asante A; Arenovich T; Fox SH
    Mov Disord; 2007 Nov; 22(15):2268-73. PubMed ID: 17876852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Onset of action of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg in subjects aged 12 years with moderate to severe seasonal allergic rhinitis: a pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies.
    Berkowitz RB; McCafferty F; Lutz C; Bazelmans D; Godfrey P; Meeves S; Liao Y; Georges G
    Clin Ther; 2006 Oct; 28(10):1658-69. PubMed ID: 17157121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.